Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Abeprazan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 13/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abeprazan SCHEMBL29443418 | 1.00 | HTR6 (0.39) | HTR6DRD2MEN1GFERKMT2A | |
| Abeprazan SCHEMBL18196939 | 1.00 | HTR6 (0.39) | HTR6DRD2MEN1GFERKMT2A | |
| Abeprazan SCHEMBL19385615 | 0.99 | HTR6 (0.40) | HTR6DRD2MEN1GFERKMT2A | |
| Abeprazan SCHEMBL29201776 | 0.97 | HTR6 (0.38) | HTR6DRD2MEN1GFERKMT2A | |
| Abeprazan SCHEMBL29201774 | 0.95 | HTR6 (0.37) | HTR6DRD2MEN1GFERKMT2A | |
| Abeprazan SCHEMBL19385601 | 0.94 | FABP4 (0.38) | HTR6DRD2MEN1GFERKMT2A | |
| SCHEMBL18190937 | 0.93 | HTR6 (0.35) | HTR6DRD2MEN1GFERKMT2A | |
| SCHEMBL18196931 | 0.93 | HTR6 (0.40) | HTR6DRD2HTR2ASMN1; SMN2 | |
| Abeprazan SCHEMBL19385619 | 0.93 | HTR6 (0.37) | HTR6DRD2MEN1GFERKMT2A | |
| Hydrochloric Acid SCHEMBL20530226 | 0.92 | HTR6 (0.40) | HTR6DRD2HTR2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117756695-A | Novel crystalline forms of highly water-soluble salts of novel 4-methoxypyrrole derivatives | 罗欣药业(上海)有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-117756694-A | High water soluble salt of new 4-methoxy pyrrole derivative and its preparation method | 罗欣药业(上海)有限公司 | 2024-03-26 | — | — | CN | claimed |
| US-20230159454-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2023-05-25 | — | — | US | claimed |
| CN-120157608-A | Non-surafaxin intermediate and preparation method thereof | 上海药坦药物研究开发有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-120118015-A | Non-surafaxin intermediate and preparation method thereof | 上海药坦药物研究开发有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-120058586-A | Non-surafaxin intermediate and preparation method thereof | 上海药坦药物研究开发有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119894867-A | Crystal form A of non-Su Lazan hydrochloride and preparation method and application thereof | 上海皓元医药股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119606953-A | Liquid pharmaceutical composition | 株式会社大熊制药 | 2025-03-14 | — | — | CN | disclosed |
| US-20250073205-A1 | NOVEL FORMULATION FOR ORAL ADMINISTRATION, COMPRISING 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-03-06 | — | — | US | disclosed |
| CN-118541141-A | Dosage regimen for non-Su Lazan injectable compositions | 株式会社大熊制药 | 2024-08-23 | — | — | CN | disclosed |
| CN-118401240-A | Pharmaceutical composition for preventing or treating triple negative breast cancer | 株式会社大熊制药 | 2024-07-26 | — | — | CN | disclosed |
| CN-117355293-A | Pharmaceutical container containing a liquid pharmaceutical composition of 1- (5- (2, 4-difluorophenyl) -1- ((3-fluorophenyl) sulfonyl) -4-methoxy-1H-pyrrol-3-yl) -N-methyl methylamine | 株式会社大熊制药 | 2024-01-05 | — | — | CN | disclosed |
| CN-116761589-A | New formulations for oral administration containing 1- (5- (2, 4-difluorophenyl) -1- ((3-fluorophenyl) sulfonyl) -4-methoxy-1H-pyrrol-3-yl) -N-methyl methylamine | 株式会社大熊制药 | 2023-09-15 | — | — | CN | disclosed |
| CN-116761589-A | New formulations for oral administration containing 1- (5- (2, 4-difluorophenyl) -1- ((3-fluorophenyl) sulfonyl) -4-methoxy-1H-pyrrol-3-yl) -N-methyl methylamine | 株式会社大熊制药 | 2023-09-15 | — | — | CN | disclosed |
| CN-116761589-A | New formulations for oral administration containing 1- (5- (2, 4-difluorophenyl) -1- ((3-fluorophenyl) sulfonyl) -4-methoxy-1H-pyrrol-3-yl) -N-methyl methylamine | 株式会社大熊制药 | 2023-09-15 | — | — | CN | disclosed |
| WO-2022250469-A1 | NOVEL INJECTABLE FORMULATION COMPRISING 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | 주식회사 대웅제약 | 2022-12-01 | — | — | WO | disclosed |
| WO-2022250472-A1 | MEDICINE CONTAINER CONTAINING LIQUID PHARMACEUTICAL COMPOSITION OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | 주식회사 대웅제약 | 2022-12-01 | — | — | WO | disclosed |
| CN-114845701-A | Liquid pharmaceutical composition of 1- (5- (2, 4-difluorophenyl) -1- ((3-fluorophenyl) sulfonyl) -4-methoxy-1H-pyrrol-3-yl) -N-methyl-amine | 株式会社大熊制药 | 2022-08-02 | — | — | CN | disclosed |
| CN-114845701-A | Liquid pharmaceutical composition of 1- (5- (2, 4-difluorophenyl) -1- ((3-fluorophenyl) sulfonyl) -4-methoxy-1H-pyrrol-3-yl) -N-methyl-amine | 株式会社大熊制药 | 2022-08-02 | — | — | CN | disclosed |
| WO-2022131844-A1 | NOVEL FORMULATION FOR ORAL ADMINISTRATION, COMPRISING 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | 주식회사 대웅제약 | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250073205-A1 | NOVEL FORMULATION FOR ORAL ADMINISTRATION, COMPRISING 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | PNMT, HNMT, MLNR | HTR6 54/4885DRD2 505/4885MEN1 769/4885 |
| US-20230159454-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | FH, FIS1, SUCNR1 | HTR6 2561/4885DRD2 3245/4885MEN1 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.